CMA refers Illumina-Pacific Biosciences deal for in-depth investigation

The Competition and Markets Authority (CMA) said it would refer the merger to a second phase investigation after the companies refused to address concerns the watchdog had raised last week.

U.S: Britain's competition watchdog said on Thursday it would launch an in-depth investigation into the planned $1.2 billion mergers between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc.

Also Read: Loxo, Illumina to partner for diagnostic tool targeting cancer

The Competition and Markets Authority (CMA) said it would refer the merger to a second phase investigation after the companies refused to address concerns the watchdog had raised last week.

The CMA's initial or first phase investigation had raised concerns about the deal's impact on the supply of specialist DNA sequencing systems in the UK.

Also Read: Illumina wins 26.7 million dollars in patent fight with Roche unit Ariosa